Tauriello et al. suggest that TGFβ mediates treatment resistance in CRC by limiting T cell infiltration of tumors, resulting in immunologically cold tumors, which can be turned hot or immune inflamed through TGFβ inhibition. Here, TGFB1 is linked to colorectal carcinoma.